Zealand Pharma CMO: Rival's delay is beneficial for Zealand

FDA has extended the review time for glucagon rescue pens from Danish Zealand Pharma's US rivals. Zealand's Chief Medical and Development Officer, Adam Steensberg, calls it beneficial for the company and is not scared of encountering the same problems.

Photo: Zealand Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles